×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| PIRAMAL PHARMA LIMITED | 11508.0 | 1131.4 | 9698.8 | 0.85 | 26,444 | 306.0 |
| Syngene International Limited | 8159.0 | 740.0 | 7993.0 | 1.83 | 26171 | 51.6 |
| WOCKHARDT LTD. | 4380.0 | 690.0 | 4130.0 | 4.25 | 24299 | 476.0 |
PIRAMAL PHARMA LIMITED, with Security Code 543635, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,054.6 | 846.4 | 994.2 | 1,024.1 | 1,525.3 | 1,063.2 | 1,284.4 | 1,248.3 | 1,689.8 | 969.9 |
| Expenses | 965.0 | 829.8 | 908.1 | 898.6 | 1,135.7 | 911.6 | 1,031.5 | 1,029.0 | 1,273.2 | 925.6 |
| Operating Profit | 89.6 | 16.6 | 86.2 | 125.5 | 389.6 | 151.6 | 252.9 | 219.3 | 416.6 | 44.3 |
| OPM % | 8.49% | 1.96% | 8.67% | 12.26% | 25.55% | 14.26% | 19.69% | 17.57% | 24.66% | 4.57% |
| Other Income | 62.9 | 26.7 | 89.1 | 33.1 | 53.2 | 36.8 | 106.4 | 24.7 | 39.5 | 180.9 |
| Interest | 33.8 | 33.8 | 28.2 | 17.4 | 27.7 | 24.9 | 30.0 | 29.2 | 30.6 | 23.2 |
| Depreciation | 53.0 | 50.4 | 50.8 | 51.6 | 52.5 | 51.9 | 53.6 | 55.5 | 61.2 | 59.4 |
| Profit before tax | 65.6 | -40.9 | 96.2 | 89.7 | 362.7 | 111.7 | 275.7 | 159.4 | 364.4 | 142.6 |
| Tax % | -36.5% | -18.4% | -19.8% | -17.1% | -24.7% | -23.6% | 23.8% | 25.5% | -23.9% | 20.6% |
| Net Profit | 41.7 | -33.4 | 77.2 | 74.3 | 273.1 | 85.3 | 210.1 | 118.8 | 277.3 | 113.1 |
| EPS in Rs | 0.35 | -0.28 | 0.61 | 0.56 | 2.06 | 0.64 | 1.59 | 0.9 | 0 | 0.85 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,716.0 | 2,163.6 | 1,748.9 | 1,911.4 | 1,958.6 | 2,552.4 | 1,951.1 | 2,241.8 | 2,204.2 | 2,754.1 |
| Expenses | 1,628.6 | 1,812.3 | 1,616.5 | 1,645.7 | 1,690.2 | 2,022.4 | 1,746.7 | 1,900.1 | 1,866.5 | 2,193.1 |
| Operating Profit | 87.3 | 351.3 | 132.3 | 265.6 | 268.4 | 529.9 | 204.5 | 341.6 | 337.7 | 561.0 |
| OPM % | 5.09% | 16.24% | 7.57% | 13.9% | 13.7% | 20.76% | 10.48% | 15.24% | 15.32% | 20.37% |
| Other Income | 82.5 | 24.5 | 38.3 | 49.2 | 29.2 | -4.1 | 19.5 | 61.1 | 12.1 | 42.0 |
| Interest | 94.7 | 104.3 | 118.5 | 109.9 | 105.9 | 114.2 | 107.0 | 107.6 | 103.3 | 103.7 |
| Depreciation | 164.4 | 184.4 | 173.6 | 184.5 | 186.3 | 196.1 | 184.6 | 192.2 | 196.8 | 242.8 |
| Profit before tax | -89.2 | 87.1 | -121.5 | 20.4 | 37.7 | 246.0 | -67.5 | 102.9 | 49.8 | 256.6 |
| Tax % | 18.5% | -51.4% | -7% | -168.9% | -171% | -58.6% | -64.6% | -94.8% | -126.9% | -46.5% |
| Net Profit | -90.2 | 50.1 | -98.6 | 5.0 | 10.1 | 101.3 | -88.6 | 22.6 | 3.7 | 153.5 |
| EPS in Rs | -0.76 | 0.42 | -0.83 | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 17% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 22% |
| TTM: | 78% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| 1 Year: | 38% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 12% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | -38% |
| TTM: | 476% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| 1 Year: | 38% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|